A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs IdeS (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms Highdes
- Sponsors Hansa Medical AB
- 04 Jan 2018 According to a Hansa Medical media release, final results are expected during the third quarter of 2018.
- 04 Jan 2018 According to a Hansa Medical media release,Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.